Quality Improvement Study of a New Generation of Whole Body PET Scanners
The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.
⁃ Eligibility Criteria for objective #1:
• Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules.
• Patients who are undergoing a planned PET-CT scan at main campus of MSK.
• Patients must be ≥ 18 years old
⁃ Eligibility Criteria for objective #2:
• Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously.
• Patients with metastatic prostate or head and neck cancer.
• Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK.
• Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK
• Patients must be ≥ 18 years old
⁃ Eligibility Criteria for objective #3:
• Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer).
• Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK.
• Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection)
• Patients must be ≥ 18 years old